<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102374</url>
  </required_header>
  <id_info>
    <org_study_id>09-0899</org_study_id>
    <secondary_id>IND 106541</secondary_id>
    <secondary_id>K23AG040708</secondary_id>
    <nct_id>NCT01102374</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents</brief_title>
  <official_title>Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The American Geriatrics Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the role of high dose vitamin D supplementation in prevention of acute
      respiratory infection in older nursing home residents. The investigators hypothesize that
      residents on high dose vitamin D supplementation will have a lower incidence of acute
      respiratory infection that those on standard dose vitamin D supplementation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blinded, parallel group, randomized controlled phase II trial of oral
      high vs. standard dose vitamin D3 supplementation administered monthly for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Acute Respiratory Infections (ARIs)</measure>
    <time_frame>12 months</time_frame>
    <description>ARIs defined as upper or lower respiratory infections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Acute Respiratory Infections</measure>
    <time_frame>12 month</time_frame>
    <description>ARIs resulting in emergency department visits or hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First ARI</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 25-hydroxyvitamin D (25OHD) Level</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Parathyroid Hormone Level</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Falls</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractures</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Upper Respiratory Infections</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lower Respiratory Infections</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Influenza-like Illnesses</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident Kidney Stones</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident Hypercalcemia</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Urinary Tract Infections</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Other Infections</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>High Dose Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Vitamin D</intervention_name>
    <description>Vitamin D3 100,000 IU monthly</description>
    <arm_group_label>High Dose Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Dose Vitamin D</intervention_name>
    <description>Vitamin D 12,000 IU monthly</description>
    <arm_group_label>Standard Dose Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo monthly</description>
    <arm_group_label>Standard Dose Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
    <arm_group_label>High Dose Vitamin D</arm_group_label>
    <arm_group_label>Standard Dose Vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 60+ years

          -  Resides in nursing home

        Exclusion Criteria:

          -  Terminal illness (expected survival &lt;6 months)

          -  Anticipated discharge within 12 months

          -  Unable to take whole or crushed tablets

          -  Active cancer, except squamous/basal cell carcinoma

          -  Severe malnutrition (body mass index &lt;18 kg/m2)

          -  Current immunosuppressive medications (including corticosteroids)

          -  Renal failure (estimated glomerular filtration rate &lt; 15 mL/min/1.73m2)

          -  Currently taking &gt;1,000 IU/d vitamin D supplementation

          -  History (or strong family history) of kidney stones

          -  History of sarcoidosis or other granulomatous disorders associated with hypercalcemia

          -  Elevated baseline hypercalcemia (albumin-adjusted serum calcium &gt;10.5 mg/dL)

          -  Baseline serum 25OHD level â‰¥ 100 nmol/L

          -  Inability to provide informed consent and no available healthcare legally authorized
             representative

          -  Inability of participant or legally authorized representative to speak/understand
             English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adit A Ginde, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ginde AA, Blatchford P, Breese K, Zarrabi L, Linnebur SA, Wallace JI, Schwartz RS. High-Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial. J Am Geriatr Soc. 2017 Mar;65(3):496-503. doi: 10.1111/jgs.14679. Epub 2016 Nov 16.</citation>
    <PMID>27861708</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <results_first_submitted>October 28, 2016</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>Respiratory Infection</keyword>
  <keyword>Nursing Home Residents</keyword>
  <keyword>Geriatrics</keyword>
  <keyword>Immunosenescence</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Vitamin D</title>
          <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
        </group>
        <group group_id="P2">
          <title>Standard Dose Vitamin D</title>
          <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Vitamin D</title>
          <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
        </group>
        <group group_id="B2">
          <title>Standard Dose Vitamin D</title>
          <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" spread="10"/>
                    <measurement group_id="B2" value="82" spread="10"/>
                    <measurement group_id="B3" value="81" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>25-hydroxyvitamin D level</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.0" spread="8.4"/>
                    <measurement group_id="B2" value="23.0" spread="9.9"/>
                    <measurement group_id="B3" value="23.0" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Acute Respiratory Infections (ARIs)</title>
        <description>ARIs defined as upper or lower respiratory infections</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Acute Respiratory Infections (ARIs)</title>
          <description>ARIs defined as upper or lower respiratory infections</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Acute Respiratory Infections</title>
        <description>ARIs resulting in emergency department visits or hospitalizations</description>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Acute Respiratory Infections</title>
          <description>ARIs resulting in emergency department visits or hospitalizations</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First ARI</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First ARI</title>
          <units>Hazard Ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59"/>
                    <measurement group_id="O2" value="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 25-hydroxyvitamin D (25OHD) Level</title>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 25-hydroxyvitamin D (25OHD) Level</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.18" spread="0.75"/>
                    <measurement group_id="O2" value="2.71" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Parathyroid Hormone Level</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Issue relating to sample collection/processing precluded measurement of PTH level in the trial</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Parathyroid Hormone Level</title>
          <population>Issue relating to sample collection/processing precluded measurement of PTH level in the trial</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Falls</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Falls</title>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractures</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Fractures</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Upper Respiratory Infections</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Upper Respiratory Infections</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lower Respiratory Infections</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lower Respiratory Infections</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Influenza-like Illnesses</title>
        <time_frame>12 months</time_frame>
        <population>collected together with lower respiratory infections (not as a separate category)</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Influenza-like Illnesses</title>
          <population>collected together with lower respiratory infections (not as a separate category)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incident Kidney Stones</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Incident Kidney Stones</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incident Hypercalcemia</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Incident Hypercalcemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Urinary Tract Infections</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Urinary Tract Infections</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Other Infections</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Vitamin D</title>
            <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Other Infections</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Dose Vitamin D</title>
          <description>100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
High Dose Vitamin D: Vitamin D3 100,000 IU monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
        </group>
        <group group_id="E2">
          <title>Standard Dose Vitamin D</title>
          <description>12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
Standard Dose Vitamin D: Vitamin D 12,000 IU monthly
Placebo: Placebo monthly
Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning, and procedural complications</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic and nutrition disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic, and mediastinal disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous disorders</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social circumstances</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <description>Adverse events were recorded at the organ system level using the MedDRA classification system</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adit Ginde, MD, MPH, Professor of Emergency Medicine</name_or_title>
      <organization>University of Colorado School of Medicine</organization>
      <phone>720-848-6777</phone>
      <email>adit.ginde@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

